showing typical intranuclear inclusion bodies which were positive with an antibody against JC virus.
In a patient with apparent primary hyperparathyroidism, the possibility of familial hypocalciuric hypercalcaemia must be considered.
CASE HISTORY
A woman was referred in 1994, at the age of 40, for control of her hypertension. Her medical history included migraine, pregnancy-induced hypertension, angina and insulin-dependent diabetes mellitus. She was obese with a blood pressure of 220/110 mmHg; the abnormal laboratory ®ndings were a total serum cholesterol of 8.9 mmol/L and serum calcium 2.89 mmol/L (normal range 2.20±2.64) with intact parathyroid hormone (PTH) 33 ng/L (5±55). She was treated with four different antihypertensive agents but her blood pressure was not controlled; there were doubts about her compliance with the medication. Her diabetes control was also poor, re¯ecting a combination of insulin resistance and dietary indiscretion. COMMENT Although rare (estimated prevalence 1 in 98 000) 2 , FHH should be excluded by urine calcium excretion studiesÐ especially when hypercalcaemia is discovered in the young (less than 40 years) and when there is a family history of hypercalcaemia. FHH was ®rst described by Foley et al. in 1972 3 . It is a benign condition inherited in an autosomal dominant manner and is caused by a loss-of-function mutation in the gene coding for the calcium sensing receptor protein (CaSR). The CaSR gene is located on chromosome 3 with other loci on chromosome 19 4 , and mutations result in an increase in the`set-point' of the parathyroid cell at which low plasma calcium stimulates PTH secretion. Homozygous loss-of-function mutations give rise to neonatal severe hyperparathyroidism and gain-of-function CaSR mutations have been observed in autosomal dominant hypercalciuric hypocalcaemia 4 (very rare).
FHH usually causes no symptoms and does not shorten life. There is no evidence of the increased incidence of peptic ulcers, bone disorders or nephrolithiasis seen in primary hyperparathyroidism, although associations reported include articular chondrocalcinosis, gallstones, pancreatitis and lipoma 5, 6 . Biochemical hallmarks include hypercalcaemia with low urinary calcium excretion, but serum PTH levels may be normal to high or even frankly raised at times 7 . The best current biochemical method of discrimination is the relationship of PTH to Ca E 8 although, because of differences in PTH assays, no single universal indicator has yet been published. Mild hypomagnesaemia has been observed in many cases 5 but was not found in the family reported here. A family history of failed neck surgery is highly suggestive of FHH and the demonstration of symptomless hypercalcaemia in family members is diagnostic. Mutation analysis will con®rm the loss-of-function mutation in the CaFR gene although this service is not yet readily available in the UK.
Although no treatment is necessary, recognition of FHH is of vital importance to avoid inappropriate parathyroid surgery, unnecessary investigations and needless prescription of low-calcium diets.
